NASDAQ:NMTC • US64130M2098
The current stock price of NMTC is 0.8132 USD. In the past month the price decreased by -9.54%. In the past year, price decreased by -32.23%.
ChartMill assigns a technical rating of 2 / 10 to NMTC. When comparing the yearly performance of all stocks, NMTC is a bad performer in the overall market: 75.47% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to NMTC. The financial health of NMTC is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months NMTC reported a non-GAAP Earnings per Share(EPS) of -0.08. The EPS increased by 83.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.38% | ||
| ROE | -50.91% | ||
| Debt/Equity | 0.18 |
8 analysts have analysed NMTC and the average price target is 2.35 USD. This implies a price increase of 188.49% is expected in the next year compared to the current price of 0.8132.
For the next year, analysts expect an EPS growth of -97.62% and a revenue growth 26.51% for NMTC
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.62 | 195.936B | ||
| ISRG | INTUITIVE SURGICAL INC | 47.53 | 172.536B | ||
| SYK | STRYKER CORP | 24.21 | 139.985B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.34 | 110.826B | ||
| IDXX | IDEXX LABORATORIES INC | 42.48 | 50.254B | ||
| BDX | BECTON DICKINSON AND CO | 11.16 | 50.113B | ||
| EW | EDWARDS LIFESCIENCES CORP | 25.52 | 44.027B | ||
| RMD | RESMED INC | 20.57 | 36.792B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16 | 36.615B | ||
| DXCM | DEXCOM INC | 27.73 | 27.309B |
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
NeuroOne Medical Technologies Corp. is a medical technology company, which engages in diagnostics, ablations, and deep brain stimulation technology for brain-related conditions. The company is headquartered in Eden Prairie, Minnesota and currently employs 18 full-time employees. The company went IPO on 2012-11-09. The company is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. The company may also pursue applications for other areas such as depression, mood disorders, incontinence and artificial intelligence. Its products include Evo cortical electrode technology for recording, monitoring, and stimulating brain tissue for up to 30 days; Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, and OneRF ablation system for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures.
NEUROONE MEDICAL TECHNOLOGIE
7599 Anagram Dr
Eden Prairie MINNESOTA US
Employees: 18
Phone: 19524261383
NeuroOne Medical Technologies Corp. is a medical technology company, which engages in diagnostics, ablations, and deep brain stimulation technology for brain-related conditions. The company is headquartered in Eden Prairie, Minnesota and currently employs 18 full-time employees. The company went IPO on 2012-11-09. The company is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. The company may also pursue applications for other areas such as depression, mood disorders, incontinence and artificial intelligence. Its products include Evo cortical electrode technology for recording, monitoring, and stimulating brain tissue for up to 30 days; Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, and OneRF ablation system for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures.
The current stock price of NMTC is 0.8132 USD. The price increased by 7.84% in the last trading session.
NMTC does not pay a dividend.
NMTC has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
NEUROONE MEDICAL TECHNOLOGIE (NMTC) has a market capitalization of 41.01M USD. This makes NMTC a Nano Cap stock.
NEUROONE MEDICAL TECHNOLOGIE (NMTC) will report earnings on 2026-02-17.
You can find the ownership structure of NEUROONE MEDICAL TECHNOLOGIE (NMTC) on the Ownership tab.